Torrent Pharmaceuticals Limited has issued commercial papers worth Rs 300 crore on March 25, 2025, as part of its short-term funding plans. The instruments have a tenure of 90 days and are set to mature on June 23, 2025.
The commercial papers carry a discount rate of 7.13% per annum, with the interest amount paid upfront. The principal amount will be repaid in full at maturity. These are unsecured instruments and do not come with any special rights, interests, or privileges.
The commercial papers are proposed to be listed on the National Stock Exchange (NSE). The company confirmed that there has been no delay in payment of interest or principal for more than three months and no comments or concerns have been raised regarding payment issues.
Torrent Pharmaceuticals continues to explore efficient financing routes to support its operational requirements and maintain liquidity.
